T. Rowe Price Associates
HPTX

T. Rowe Price Associates’s HYPERION THERAPEUTICS INC COM STK (DE) HPTX Stock Holding History

T. Rowe Price Associates’s Portfolio HPTX Stock Details HPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-40,089
Closed -$962K – 2594
2014
Q4 		$962K Sell
40,089
-38,263
-49% -$863K ﹤0.01% 1733
2014
Q3 		$1.98M Sell
78,352
-51,181
-40% -$1.27M ﹤0.01% 1577
2014
Q2 		$3.38M Buy
129,533
+28,841
+29% +$741K ﹤0.01% 1499
2014
Q1 		$2.6M Buy
+100,692
New +$2.73M ﹤0.01% 1521

Other funds holding HPTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's HPTX Position: Q1 2015 in Review

T. Rowe Price Associates sold out of HYPERION THERAPEUTICS INC COM STK (DE) (HPTX) in Q1 2015, closing a stake of 40,089 shares — an estimated $962K sold.

T. Rowe Price Associates first reported a position in HPTX in Q1 2014 and held it in 4 quarters. The position peaked at $3.38M in Q2 2014. 134 funds tracked by Wall St. Rank hold HPTX as of Q1 2015.

  • T. Rowe Price Associates reported no remaining HYPERION THERAPEUTICS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 40,089 HYPERION THERAPEUTICS INC COM STK (DE) shares in Q1 2015, an estimated $962K.
  • T. Rowe Price Associates first reported a position in HYPERION THERAPEUTICS INC COM STK (DE) in Q1 2014 and held it in 4 quarters.
  • T. Rowe Price Associates's HYPERION THERAPEUTICS INC COM STK (DE) position peaked at $3.38M in Q2 2014.
  • 134 funds tracked by Wall St. Rank held HYPERION THERAPEUTICS INC COM STK (DE) as of Q1 2015.

Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.